Pure Global
NCT05732688

Drug-screening in AML at Relapse for Targeted Treatment

University Hospital Inselspital, Berne·ClinicalTrials.gov·diagnostic testRecruiting
View on ClinicalTrials.gov →
Study focus
Disease/Condition
AML
Drug/Device/Intervention
Image-based ex-vivo drug screening platform (pharmacoscopy)
Study type
Interventional
Intervention type
diagnostic test
Sponsor & location
Primary sponsor
University Hospital Inselspital, Berne
Location
Berne, Switzerland
Timeline & enrollment
Phase
N/A
Start date
Jan 01, 2022
End date
Jun 01, 2024
Enrollment
30 participants
Primary outcome

Treatment with identified effective drug

Summary

This is a non-randomised clinical study investigating subsequent patients with specific AML
 treatment started between January 1, 2022 until December 31, 2022.
 
 Patients with relapsing disease are planned to be analyzed in this study

ICD-10 classifications
Acute myeloblastic leukaemia [AML]
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT05732688
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT05732688 through Pure Global AI's free database. This phase not specified trial is sponsored by University Hospital Inselspital, Berne and is currently Recruiting. The study focuses on AML. Target enrollment is 30 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.